Clinical Trial

CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome

Investigator
Complete title:
A Pilot Study of CPX-351 (Vyxeos) for Transplant Eligible, Higher Risk Patients with Myelodysplastic Syndrome
Trial phase:
Phase I
Study ID:
NCT03572764
Local study ID:
RG1004945
Summary:
This is a pilot and feasibility study of transplant eligible, higher risk myelodysplastic syndrome (MDS) patients to determine the safety and tolerability of a lower -dose and higher-dose CPX-351 regimen, with secondary objectives including complete remission (CR) rates and proportion of patients proceeding to transplant.
Trial keywords:
Myelodysplastic Syndromes (MDS)
Enrollment status:
Recruiting
Trial eligibility
** For Eligibility information, please click on the "Look up trial at NIH" link above **
Other eligibility criteria may apply.
Trial exclusions
Other exclusion criteria may apply.
Learn more

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Contact us
phone 1-800-606-7800
Toll-free